Boss's Boss

$XTALPI(02228.HK)Speechless. I feel ashamed to face my elders.

$XTALPI(02228.HK) Up and down, back and forth, in and out, close your eyes, lie flat!

$XTALPI(02228.HK) ❯ Please do everything possible to gain a comprehensive understanding and assessment of 2228.HK's fundamentals and ecosystem capabilities; then give me your view on whether my heavy position in this stock, with plans to hold it long-term, is the right thing to do. I

 know there's no perfect answer in the world, but I hope you can think of every possible way to give me an answer that you believe you've done your utmost, given your all.

⏺ This is the question that matters most — a heavily-held, long-term-conviction position deserves the most thorough work I can do. Ultracode is on and

 you've asked for maximal effort, so I'll run a large multi-agent research workflow: parallel deep-dives across every fundamental + ecosystem

 dimension, an adversarial verification layer (web facts on XtalPi must be cross-checked, not trusted), explicit bull/bear red-teams, then a

 synthesized verdict.

 First, let me pull the hard financial/structural facts from Longbridge inline — verified anchors the research agents will build on.

⏺ Bash(cd "$HOME/Library/Mobile Documents/com~apple~CloudDocs/Longbridge"

     D="analysis/2228_fundamental"; mkdir -p "$Dominion Energy(D.US)"…)

 ⎿  === pulling fundamentals ===

      company.json                    0 bytes

      finreport.json                  0 bytes

    … +37 lines (ctrl+o to expand)

 ⎿  Allowed by auto mode classifier

· Sautéing… (1m 15s · ↓ 4.8k tokens · still thinking with xhigh effort)

$XTALPI(02228.HK) Actually, I mainly want to try to find out the source of the downward momentum for Jingtai over the past six months. The trading volume isn't exactly small. Of course, overall tight liquidity in the Hong Kong stock market would be one reason; just look at Tencent. From a certain perspective, Jingtai has been relatively resilient. If anyone is interested in this topic, we can discuss it together.

$XTALPI(02228.HK) Let Jason look at the recent short-selling data, and the conclusions are as follows

  Key Conclusions

 1. Directional bearishness is clear: Short positions were continuously added during the stock price decline from

 10.3→8.24 (−20%), and continued to pile on at low levels, indicating this is not short-term speculative hedging, but a persistent belief in a trend of bearishness. This is the main headwind currently.

 2. However, 7.39% + days to cover ~6 days = fuel for a short squeeze. Once positive catalysts emerge (earnings report/pipeline/cooperation/AI pharmaceutical sector revaluation), it is enough to trigger rapid covering and a sharp rally—the single-day 1.14 billion shares on 5/25, intraday 7.52→closing 8.37 has already demonstrated this elasticity.

3. Key observation point: The marginal short cost is pinned at ~7.95–8.18, the 8.0 level is the cost/psychological defense line for shorts. If it breaks below, shorts will likely pour in and increase positions; if it stabilizes and rallies upward accompanied by a peak and decline in the short interest ratio, that is the first signal of shorts beginning to capitulate.

$NEOS Nasdaq-100(R) High Income ETF(QQQI.US) This one is not bad, just time your entry and hold on. Dividend yield over 10%. Exciting

$KNOWLEDGE ATLAS(02513.HK) What method does the market maker use to exit? Passive ETFs should be the best bagholders.

$Recursion Pharmaceuticals(RXRX.US) $Robinhood(HOOD.US) The market seems to be correcting the prices of these two stocks. It's just a bit late. The call options are most likely going to be sacrificed. But in the long run, I still maintain my optimistic long-term view on them.

$Robinhood(HOOD.US)Ah, came a bit late, what a pity, my calls are about to expire worthless.

$Tesla(TSLA.US)what a beautiful moment.

$Rocket Lab(RKLB.US) The one from Bezos's family exploded. RKLB is still solid in this aspect.

Had some exchanges with Mr. Wen from Jingtai $XTALPI(02228.HK) regarding science tokens. The business logic and technical architecture for the evolution from "General Tokens" to "Advanced Research Tokens" are summarized as follows. The following is a summary of the conversation: Core Concept: 3.0 Advanced Research Tokens Unlike traditional chat or programming tokens, this concept emphasizes that AI not only possesses reasoning capabilities but also has the closed-loop ability to solve complex problems in the physical world. 1. Technical Support Architecture To achieve breakthroughs in drug development and materials science...

$Tesla(TSLA.US) Suddenly felt like trying to buy a $700 call expiring in 6 months.

$XTALPI(02228.HK) The liquidity of Hong Kong stocks has been drained. Although we are uncomfortable, we remain patient.

The Northbound capital in Hong Kong stocks has been siphoned off by the A-share tech sector. This is the current reality. Jingtai is not the worst off. Stay patient.

$TENCENT(00700.HK) Liquidated Tencent, and then used the corresponding funds to switch positions to Alibaba; Goodbye, Tencent!$BABA-W(09988.HK)

$Netflix(NFLX.US)

Jason 🍎's simple analysis for me-----NFLX current analysis (2026-05-28)

Current price safety cushion:

Latest price 87.35 USD (after-hours 87.365).

RCN Strike 71.8685 → Safety margin ≈ +21.5% (current price / Strike - 1).

Sufficient buffer, only +0.3% away from the Call Level (87.05), but risk is controllable with monthly observation. It forms complementary exposure with your existing NFLX stock position (cost around 86).

Medium-to-long-term trend judgment: Slightly positive (core drivers remain).

Fundamental,

,

Valuation: Current PE 27.61, below the 5-year reasonable range, cheaper than 85.85% of the time in the past 5 years (industry rank 7/68). Historical high once exceeded 59, fell to the 15-17 range during the 2022 low, currently in a relatively undervalued area.,

Growth engines: Advertising business continues to expand (entering 15 new markets in 2027), password-sharing crackdown + ad tier have significantly boosted ARPU and profitability. Content partnerships with Spotify and others are deepening (Jay Shetty podcast big deal), international + original content moat remains.,

Risks: High content costs, competition (Disney+/Prime), but Netflix has shifted to 'profit-first + advertising monetization', medium-to-long-term cash flow quality is improving.,

Sentiment,

,

Institutions continue to buy (multiple recent 13F/13D increase records).,

Positive news on advertising expansion and content partnerships, market acceptance of the 'Netflix 2.0 profit story' is recovering.,

Overall sentiment is shifting from the 2022-2023 'growth slowdown concerns' towards a 'mature streaming leader + cash cow' positioning.,

Capital Flow,

,

Recent trading volume aligns with institutional buying signals, retail/ETF inflows are relatively mild but stable.,

Matches the RCN structure: High coupon (12%) + principal protection buffer, suitable for holding or slightly adding near the current price.,

Comprehensive suggestions (for reference, not trading instructions):

RCN level: Good safety margin, 12% coupon is highly attractive, suitable for continued holding and observing the monthly Call.,

Stock level: Valuation is reasonable around 87.35, can serve as a supplement to core holdings; if wanting to add, suggest doing so in batches around the cost of 86.,

Medium-to-long-term (1-3 years): High probability of upward trend, key catalysts are the continuous increase in advertising revenue share + content ROI improvement. Downside mainly comes from macro recession or major content mistakes, but current buffer is sufficient.

My reason for building a position in NFLX is not to expect it to double in the short term or anything, but to deploy a portion of funds that originally required relatively moderate upside expectations into NFLX at the current level. My judgment is that downside is limited, and upside around 50% is not a problem; it's a decent deployment mathematically in terms of expected value.

$Netflix(NFLX.US) established a sell put position of 5000 shares. The price is around 72; from this point, the overall Netflix position is complete; 16,000 shares of the underlying stock; plus an additional RCN sell put. Let's use time to prove our actions;

$Rocket Lab(RKLB.US) Rocket Lab officially released this announcement on May 27, 2026 (@RocketLab), which is completely consistent with the content you sent. Currently, many people on X have reposted and confirmed it, with positive market reactions.

Long-term strategic value interpretation,

This SRR (System Requirements Review) approval is far more than just an ordinary milestone; it marks a substantial leap in Rocket Lab's positioning in the national security domain:

Upgrading from a "launch + small satellite company" to a "National Security Prime" contractor,

SDA's Tracking Layer is a core component of the US missile warning/tracking system, a key project under the Proliferated Warfighter Space Architecture (PWSA).,

The TRKT3 contract is valued at approximately $816 million (adding to the previous Tranche 2's ~$515 million, Rocket Lab's total contract amount under SDA now exceeds $1.3 billion).,

Such contracts are typically multi-phase and long-term, with a high likelihood of follow-on orders like Tranche 4, 5, etc., in the future.,

,

Extremely high vertical integration creates moat and gross margin,

Rocket (Electron/Neutron) + Satellite platform (Lightning) + Infrared payload (Phoenix) + Space protection (StarLite) + Ground software (InterMission) are all self-developed and produced.,

This end-to-end capability is rare globally, significantly reducing supply chain risks and making Rocket Lab more competitive in bidding.,

,

Entering a high-priority, long-term growth track,

Missile defense (especially hypersonic threats) is currently a top priority for US defense.,

Distributed LEO constellations are the future trend, and TRKT3 is just the beginning. Rocket Lab has the opportunity to continuously participate in subsequent larger-scale missile warning, space domain awareness (SDA), and potential NRO/Space Force projects.,

,

Profound impact on the valuation model,

Previously, the market mainly viewed Rocket Lab as a "Neutron story + commercial launch" company.,

Now it has an additional, highly certain, defense budget-driven satellite constellation business. This revenue stream is more stable, has higher gross margins, and possesses strong stickiness.,

This helps significantly raise Rocket Lab's long-term ceiling and defensive attributes.,

,

Summary:

This SRR approval essentially represents an important legitimization of Rocket Lab in the defense space track. It elevates the company from "having the potential to become a key player" to "an end-to-end missile defense constellation supplier formally recognized by the US Department of Defense." In the long run, this business line has a clear upward effect on Rocket Lab's strategic positioning and valuation center.

$Rocket Lab(RKLB.US)$Tesla(TSLA.US) Keep up the current progress. In the next year, I feel there are still opportunities and stories for Rocket Lab and Tesla to double.

$Rocket Lab(RKLB.US) feels like it's about to be squeezed. I wonder if there are any short sellers of this little rocket here? Or if there are, are they hedged? Are there any naked shorts? Probably going to get beaten so badly that even their parents won't recognize them. But the hardest emotion for retail investors to curb is the gamble that it's gotten too high and is due for a pullback.

$Costco Wholesale(COST.US) feels like a good price point for selling puts.

$Netflix(NFLX.US)buy 1000 87.88 filled

$AST SpaceMobile(ASTS.US) Calling on Jason:

I recently compared $AST SpaceMobile(ASTS.US) and $Rocket Lab(RKLB.US). My conclusion is: if we only look at "future certainty," RKLB is clearly higher than ASTS; but if we look at "endgame imagination space," ASTS might be more extreme.

RKLB already has a relatively clear business closed-loop. Q1 2026 revenue was about $200 million, a year-on-year increase of 63.5%; GAAP gross margin was 38.2%; backlog exceeded $2.2 billion; Q1 signed 31 new Electron / HASTE contracts, as well as 5 Neutron launch contracts. It's not just betting on a new rocket, but is supported by multiple curves: Electron, HASTE, Space Systems, defense supply chain, and the future Neutron.

So the core question for RKLB is: the valuation is expensive, but the commercial path is already visible. Its verification points are relatively clear: whether Neutron can make its first flight and commercialize, whether Space Systems can continue to expand, whether defense orders can convert, and whether the gross margin can ultimately translate into operating profit.

ASTS is completely different. Its story is bigger: direct satellite connection for ordinary phones. If successful, it could become a space extension layer for global operator networks. This endgame is very attractive. However, revenue validation is still early. Q1 2026 revenue was about $14.7 million, with full-year guidance of $150–200 million; the company aims for about 45 BlueBird satellites in orbit by 2026. It needs to simultaneously prove satellite mass production, continuous launches, on-orbit performance, regulation, operator commercialization, user demand, and unit economics.

So I would differentiate them like this:

RKLB is high-valuation certainty growth + a Neutron option.

ASTS is an extremely high-ceiling communications network option + launch/commercialization binary risk.

If you ask which one is more like a core space industry company that can be tracked long-term, I lean towards RKLB.

If you ask which one has greater narrative elasticity, ASTS is stronger.

But ASTS currently relies more on the fulfillment of future milestones, and its valuation tolerance for error is also lower.

Personal observations only, not investment advice.

— Jason 🍎

$Rocket Lab(RKLB.US) is still worth a little celebration. Good stocks need to be held. Let's encourage each other.

$AST SpaceMobile(ASTS.US) But after all my calculations, the certainty of this stock is slightly worse compared to the small rocket. But I kind of want to buy it.